Table 1

MRN, clinical, epidemiological, and serological data of control subjects, patients with T2D with DN, and patients T2D without DN

Control subjectsT2D no DNT2D DNP (ANOVA)
FA0.549 ± 0.0520.531 ± 0.0380.473 ± 0.056<0.001***
Age (years)55.9 ± 12.663.1 ± 10.568.7 ± 8.10.001**
Sex
 Female799n.a.
 Male31619n.a.
Disease duration (years)n.a.7.5 ± 5.813.5 ± 9.80.079ns
NSS0 ± 01.00 ± 1.946.24 ± 3.09<0.001***
NDS0.80 ± 1.320.87 ± 0.975.46 ± 1.95<0.001***
Tibial CMAPs (mV)17.85 ± 6.9013.51 ± 5.459.26 ± 7.000.004**
Tibial NCVs (m/s)47.33 ± 4.6642.64 ± 4.8240.44 ± 4.890.002**
Tibial DMLs (ms)3.53 ± 0.733.93 ± 0.795.32 ± 2.860.006**
Peroneal CMAPs (mV)7.66 ± 1.256.56 ± 3.943.64 ± 2.72<0.001***
Peroneal NCVs (m/s)45.86 ± 4.0240.09 ± 6.03137.67 ± 5.960.004**
Peroneal DMLs (ms)3.79 ± 0.313.93 ± 0.905.40 ± 2.340.021*
Sural SNAPs (µV)7.20 ± 3.005.71 ± 3.614.20 ± 2.010.043*
Sural NCVs (m/s)48.00 ± 4.5047.78 ± 5.3827.86 ± 22.550.031*
hsTNT (pg/mL)6.00 ± 1.708.21 ± 5.1111.64 ± 5.38<0.001***
proBNP (pg/mL)60.30 ± 43.69115.8 ± 146.4109.4 ± 87.780.283ns
HbA1c (%)5.48 ± 0.446.94 ± 1.496.98 ± 1.14<0.001***
HbA1c (mmol/mol)36.28 ± 2.2252.34 ± 2.7547.39 ± 2.5<0.001***
Creatinine (mg/dL)0.78 ± 0.140.85 ± 0.240.84 ± 0.160.577ns
GFR–CKD-EPI (mL/min)89.95 ± 11.8989.02 ± 17.1185.84 ± 14.720.750ns
Cystatin C (mg/L)0.837 ± 0.0920.949 ± 0.2050.904 ± 0.3180.174ns
Serum cholesterol (mg/dL)
 Total211.00 ± 40.73191.20 ± 38.80198.00 ± 45.900.472ns
 HDL cholesterol67.20 ± 17.3149.13 ± 14.2154.11 ± 16.530.014*
 LDL cholesterol122.20 ± 38.66108.60 ± 36.05111 ± 42.340.653ns
Triglycerides (mg/dL)108.70 ± 44.61190.40 ± 120.30170.30 ± 96.780.095ns
  • All values are displayed as mean ± SD. DML, distal motor latencies; GFR, glomerular filtration rate; n.a., not applicable.

  • Level of significance: nsP > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001.